Company/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ende

Company/Investor Contact:

CJones & Associates Public Relations

Biopharma Announces Financial Results in its Quarterly Report for the

Nine Months Ended September 30, 2016

Call Scheduled for Tuesday, November 15, 2016 at 11:00 AM EST

- November 14, 2016 - Hemispherx Biopharma (NYSE MKT: HEB) announces the filing of its Quarterly Report and its financial

results for the nine months ended September 30, 2016. The net loss was approximately $6,329,000 or $(0.30) per share as compared

to a net loss of $12,093,000 or ($0.62) per share for the same nine month period in 2015. Cash, cash equivalents and marketable

securities were approximately $8,009,000 at September 30, 2016 as compared to $8,910,000 as of December 31, 2015.

Biopharma recently made changes to its senior management team and implemented austerity measures which included the reduction

of executive compensation and elimination of non-essential contractors and personnel. These measures have resulted in a significant

reduction in costs and expenses. The Company is now focusing on commercial success by seeking co-development partners and working

closely with the research and regulatory communities to bring disease fighting technologies to the world.

of this quarter, on August 18, 2016, we received approval of our New Drug Application ("NDA") from Administracion

Nacional de Medicamentos, Alimentos y Tecnologia Medica ("ANMAT") for commercial sale of rintatolimod (U.S. tradename:

Ampligen ) in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS").

The product will be marketed by GP Pharm, our commercial partner in Latin America. We believe that rintatolimod is the first drug

to receive approval for this indication anywhere in the world.

will host a conference call at 11:00 a.m. Eastern Standard Time (EST) on Tuesday, November 15, 2016 to provide a general business

update. Hemispherx will respond to various stockholder questions submitted prior to the call.

of the conference call will be available on the Company's website approximately one hour following the conclusion of the

Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug

entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection

and the experimental therapeutics rintatolimod (tradenames Ampligen or Rintamod ) and Alferon LDO. Rintatolimod

is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system,

including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various

severely debilitating and life threatening diseases. Because both Rintatolimod and Alferon LDO are experimental in nature,

they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical

trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N

Injection ), approved for sale in the U.S. and Argentina. The FDA approval of Alferon N Injection is limited to the treatment

of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon N approval

in Argentina includes the use of Alferon N Injection (under the pending brand name "Naturaferon") for use in any patients

who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. Rintamod

has received approval in the Argentine Republic to treat severe cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

It will be marketed by GP Pharm, Hemispherx's commercial partner in Latin America. The Company wholly owns and exclusively

operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit

that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant

to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as (intends", "plans",

"potential", "potentially", "possible" and similar expressions are intended to identify forward-looking

statements. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its

plans will be achieved. These forward-looking statements are neither promises nor guarantees of future performance, and are subject

to a variety of risks and uncertainties, many of which are beyond Hemispherx's control, which could cause actual results

to differ materially from those contemplated in these forward-looking statements. Examples of such risks and uncertainties include

those set forth in the Disclosure Notice, below, as well as the risks described in Hemispherx's filings with the Securities

and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K. You are cautioned not to place undue reliance

on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update

or revise the information contained in this press release, whether as a result of new information, future events or circumstances

or otherwise revise or update this release to reflect events or circumstances after the date hereof.

in this press release includes certain "forward-looking" statements including without limitation statements about additional

steps which the FDA may require and Hemispherx may take in continuing to seek commercial approval of the Ampligen NDA for

the treatment of Chronic Fatigue Syndrome in the United States. The final results of these and other ongoing activities could

vary materially from Hemispherx's expectations and could adversely affect the chances for approval of the Ampligen

NDA in the United States and other countries. The clinical studies referenced herein have been previously reviewed by the FDA

and are not, in and of themselves, a sufficient basis for approval in the United States. Any failure to satisfy the FDA regulatory

requirements or the requirements of other countries could significantly delay, or preclude outright, approval of the Ampligen

NDA in the United States and other countries.

contained in this news release, other than historical information, should be considered forward-looking and is subject to various

risk factors and uncertainties including, but not limited to, general industry conditions and competition; general economic factors;

the Company's ability to adequately fund its projects; the impact of pharmaceutical industry regulation and healthcare legislation

in the United States and internationally; trends toward healthcare cost containment; technological advances, new products and

patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the

Company's ability to accurately predict the future market conditions; manufacturing difficulties or delays; dependence on

the effectiveness of the Company's patents and other protections for products; and the exposure to litigation, including

patent litigation, and/or regulatory actions; and numerous other factors discussed in this release and in the Company's

filings with the Securities and Exchange Commission. The production of new Alferon API inventory will not commence until

the validation phase is complete. While the facility is approved by FDA under the Biological License Application ("BLA")

for Alferon , this status will need to be reaffirmed by a successful Pre-Approval Inspection by the FDA prior to commercial

sale of newly produced inventory product. The validation phase was delayed to repair the damage caused by a flood that occurred

on January 5, 2016 at the facility. If and when we obtain a reaffirmation of FDA BLA status and have begun production of new Alferon

API, we will need FDA approval as to the quality and stability of the final product to allow commercial sales to resume. With

regard to our NDA for Ampligen to treat CFS, we note that there are additional steps which the FDA has advised us to take

in our seeking approval. The final results of these efforts and/or any other activities could vary materially from Hemispherx's

expectations. Any failure to satisfy the FDA regulatory requirements or the requirements of other countries could significantly

delay, or preclude outright, approval of Ampligen in the United States and other countries. No evidence is suggested that

Ampligen will be commercially approved for any treatment or that Alferon N Injection will be commercially approved for

potential new treatment indications or for new manufacturing procedures. Approval of Rintamod for CFS in the Argentine Republic

does not in any way suggest that the Ampligen NDA in the United States will obtain commercial approval. Also, it is noted

that ANMAT approval is only an initial, but important, step in the overall successful commercialization. Namely, additional steps

required for commercialization in Argentina will require, among others, an appropriate reimbursement level, appropriate marketing

strategies, completion of manufacturing preparations for launch (including possible requirements for approval of final manufacturing,

etc., and there are no assurances as to whether or when such multiple subsequent steps will be successfully performed to result

in an overall successful commercialization and product launch.